Compare Baxter International Inc (BAX) vs F5 Inc (FFIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs F5 Inc — how do they compare? Baxter International Inc trades at $21.78 (market cap $11.26B), while F5 Inc trades at $428.94 (market cap $24.33B). The key difference: F5 Inc is far larger — about 2.2× Baxter International Inc's market cap, and Baxter International Inc pays a 0.92% dividend while F5 Inc pays none. Which is the better fit depends on your goals.
| BAX | FFIV | |
|---|---|---|
Market Cap | $11.26B | $24.33B |
Sector | Health | Technology |
52-Week High | $29.22 | $431.26 |
52-Week Low | $15.80 | $223.99 |
Enterprise Value | $18.93B | $23.15B |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
F5 Networks (FFIV) trades at $420.95, down 2.19% today, with a bullish technical signal from moving averages and strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, with Q1 2026 EPS of $3.90 exceeding the $3.46 estimate. Revenue growth accelerated to $3.09 billion in 2025, while net income margins expanded to 22.42%. Recent strategic moves include expanding AI security capabilities through the SurePath AI acquisition and new executive appointments.
FFIV presents a mixed outlook with strong operational execution offset by premium valuations. The stock trades above analyst consensus target of $397, though institutional sentiment remains positive with 40% buy ratings. Key risks include competitive pressures in cybersecurity and execution challenges in AI integration. Earnings growth and margin expansion remain the primary catalysts for further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →
